Best Genomics Companies in Shanghai, China
The 56 best Genomics companies in Shanghai, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: 3DMed.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Shanghai
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3DMed Provider of personalized diagnostic treatment solutions for cancer | $365M | 68 mo ago | Series D | 2010 | Simon Shung Founder | 215 | — | — |
| 2 | Sangon Biotech Provider of research services and reagents and kits | $300M | 38 mo ago | Series B | 2003 | — | 951 | — | — |
| 3 | Singlera Genomics Developer of the NGS-based platform to detect cancer 72Moat top 21%Funding top 26%Market top 30%Patents top 33% All 6 signals ▾Moattop 21% Fundingtop 26% Markettop 30% Patentstop 33% Innovationtop 41% Globalbottom 40% Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $209M | 24 mo ago | Series B | 2014 | — | 300 | 29 patents Liquid biopsy DNA methylation biomarkers for cancer detection and tumor assessment | — |
| 4 | Siwei Biotechnology Developer of nanocarrier delivery platform for mRNA vaccines | $206M | 61 mo ago | Deadpooled | 2016 | Li Hangwen Founder | — | — | — |
| 5 | Innovative Cellular Therapeutics Developer of CAR-T cell therapies for blood cancers and solid tumors | $97M | 58 mo ago | Series C | 2009 | Lei Xiao CEO | 14 | 73 patents Engineered immune cells for adoptive cell therapy targeting tumor antigens | — |
| 6 | Zensun Developer of protein and gene therapies for a wide range of diseases | $76M | 104 mo ago | Public | 2000 | Zhou Mingdong Founder & CEO | 81 | — | — |
| 7 | RONA Therapeutics Developer of oligonucleotide therapeutics to treat multiple diseases 40Patents top 31%Moat top 32%Funding top 40%Innovation top 42% All 7 signals ▾Patentstop 31% Moattop 32% Fundingtop 40% Innovationtop 42% Talentbottom 49% Globalbottom 43% Marketbottom 40% Patents: 27 patents matched (strict assignee match) · 27 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 27 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 23 mo ago | Series A | 2021 | Stella Shi Founder | — | 27 patents RNAi therapeutics and targeted siRNA/ dsRNA delivery for disease-modifying gene regulation | — |
| 8 | Genechem Products and services in molecular biology | $56M | 75 mo ago | Series C | 2002 | Honghua Qu Founder | 529 | — | — |
| 9 | Epigenic Therapeutics Developer of gene editing therapies for a wide variety of diseases 57Funding top 26%Patents top 28%Moat top 32%Innovation top 37% All 9 signals ▾Fundingtop 26% Patentstop 28% Moattop 32% Innovationtop 37% AItop 45% Talentbottom 49% Newsbottom 42% Marketbottom 40% Globalbottom 40% Funding: Raised $52.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Patents: 43 patents matched (strict assignee match) · 43 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $52M | 10 mo ago | Series B | 2021 | Bob Zhang Co-Founder & CEO | — | 43 patents Epigenome editing tools for therapeutic gene repression (viral, metabolic, angiogenesis targets). | — |
| 10 | Zhengxu Biotechnology Developer of gene-editing technology to treat genetic diseases | $47M | 56 mo ago | Series C | 2020 | Chen Jia Founder | — | — | — |
| 11 | Shanghai Zhongke New Life Biological Technology Provider of sequencing and bioinformatics services | $28M | 27 mo ago | Series C | 2003 | Chen Wei CEO | 90 | — | — |
| 12 | Ringcode Bio Developer of a circular RNA technology platform for therapeutics | $20M | 55 mo ago | Seed | 2021 | Zefeng Wang Co-Founder | — | — | — |
| 13 | Huida Developer of gene therapies for the treatment of multiple disease conditions | $19M | 50 mo ago | Series C | 2018 | Shi Linyu Co-Founder | 150 | 2 patents Anti‑freeze water‑pipe valves and theft‑resistant fastening screws. | — |
| 14 | Polaris Biology Single-cell diagnostic platform for detection of tumors | $18M | 72 mo ago | Series B | 2016 | Yuchong Wang CEO | — | 32 patents Advanced mass spectrometry hardware for single-particle analysis and biomolecule labeling | — |
| 15 | Topgen Provider of gene mapping and detection of tumors | $17M | 72 mo ago | Series C | 2012 | — | 141 | — | — |
| 16 | Yipu Bio Developer of diagnostic tests for the detection of cancer | $16M | 51 mo ago | Series B | 2018 | Hua Lin CEO | — | — | — |
| 17 | Wancheng Gene Provider of single-cell multi-omics technology for research and industrial-grade production | $16M | 54 mo ago | Series A | 2017 | Wu Ziniu Co-Founder | — | — | — |
| 18 | GloriousMed Provider of gene testing services for immunodiagnosis and treatment | $16M | 57 mo ago | Series B | 2015 | Jin Ge CEO | — | — | — |
| 19 | Ouyi Biomedical Technology Provider of multi-omics testing services | $16M | 56 mo ago | Series A | 2009 | Dong Dong Co-founder | — | — | — |
| 20 | Rendu Biotechnology Developer of RNA-based diagnostic solutions for various medical conditions | $15M | 124 mo ago | Series B | 2007 | — | 529 | — | — |
| 21 | Shanghai Doning Biotechnology Provider of cell culture media | $15M | 55 mo ago | Series C | 2005 | — | 704 | — | — |
| 22 | YolTech Developer of gene editing and LNP delivery platforms for therapeutics 27Funding top 37%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 37% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $14.1M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 27/100 | $14M | 10 mo ago | Series B | 2021 | Yuxuan Wu Founder & CEO | — | — | — |
| 23 | Milestone Biotechnologies Company solutions for various applications including single-cell mutation analysis, CDMO services and… 24Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 36% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $13.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $14M | 18 mo ago | Series A | 2014 | Zhang Jinbao Founder & CEO | — | — | — |
| 24 | Bendao Gene Technology Provider of a gene-editing platform for the treatment of genetic diseases | $11M | 63 mo ago | Series A | 2018 | Cai Yujia Founder | — | — | — |
| 25 | Hezhuo Biotechnology Provider of cell biology testing services | $7M | 79 mo ago | Series A | 2016 | Yang Shen CEO | — | — | — |
| 26 | Anpac Developer of novel multi-level and multi-parameter liquid biopsy tests for cancer | $2M | 126 mo ago | Series B | 2008 | Herbert Yu Co-Founder | 75 | — | — |
Top 12 Genomics companies in Shanghai
#1
Series B · Shanghai, Shanghai · founded 2021$52Mraised▾
Developer of gene editing therapies for a wide variety of diseases. The company uses proprietary and patented technology platform Artificial intelligence (AI) algorithms and lipid nanoparticle (LNP) medicine delivery system to deliver medicine to target cells and tissues ex vivo and in vivo in ocular, neurodegeneration, metabolic, and rare disease models.
- Sep 2025Series B$60M
- Aug 2023Series A$32M
- Aug 2022Seed$20M
#2
Series B · Shanghai, Shanghai · founded 2021$14.1Mraised▾
Developer of gene editing and LNP delivery platforms for therapeutics. It focuses on creating novel tools for genome editing using metagenomics data. It develops in vivo gene-editing medicines for genetic, metabolic, cancer, and cardiovascular diseases. It is researching treatments for diseases such as familial hypercholesterolemia and hereditary transthyretin amyloidosis.
- Sep 2025Series B$45M
- Nov 2023Series A$14.1M
- Feb 2022Angel—
- Series A—
#3
Series B · Pudong, Shanghai · founded 2014 · 300 employees$208.6Mraised▾
Developer of the NGS-based platform to detect cancer. The company has methylation haplotyping technology for detecting cancer biomarkers. Tumor cells release circulating tumor DNA (ctDNA) into the blood when undergoing apoptosis or necrosis and this ctDNA is detected as cancer biomarkers. The company has developed a PanSeer assay that measures distinct tumor-specific methylation patterns in adjacent methylation sites. It can detect cancer up to four years before conventional diagnosis.
- Jul 2024Series B$13.8M
- Jun 2022Series B$44.9M
- Dec 2020Series B$150M
- 2018Series A—
#4
Series A · Shanghai, Shanghai · founded 2021$68Mraised▾
Developer of oligonucleotide therapeutics to treat multiple diseases. The company focuses on the discovery and development of modular and programmable RNA medicines targeting disease areas across metabolic diseases, neurological diseases, and ophthalmology diseases by using proprietary delivery systems.
- Jul 2024Series A$35M
- Apr 2022Series A$33M
#5
Series A · Pudong, Shanghai · founded 2014$13.6Mraised▾
Company solutions for various applications including single-cell mutation analysis, CDMO services and agriculture. It specializes in the production and supply of various biological products, including single-cell mutation analysis, PBMC and immune cell subtypes, animal liver cells, and in vivo and in vitro drug efficacy.
- Jan 2025Series A$13.6M
- Aug 2023Series A—
#6
Series B · Shanghai, Shanghai · founded 2003 · 951 employees$300Mraised▾
Provider of research services and reagents and kits. The company offers services like oligos, genes, and peptides syntheses, DNA and NGS sequencing, protein, antibody, and molecular biology-related services. It also sells PCR, enzyme, and other reagents, ELISA, PCR, and other kits.
- Apr 2023Series B$290M
- Aug 2010Series A$10M
#7
Series C · Shanghai, Shanghai · founded 2003 · 90 employees$28.3Mraised▾
Provider of sequencing and bioinformatics services. The company provides services such as high-throughput sequencing, proteomics, PTM modification, metabolomics, post-translational modification group, metabolite, biomedical structure characterization services, and bioinformatics services.
- Apr 2024Series C—
- Aug 2022Series B—
- Apr 2020Series A$28.3M
#8
Series D · Shanghai, Shanghai · founded 2010 · 215 employees$365.1Mraised▾
Provider of personalized diagnostic treatment solutions for cancer. The company depends on an individual's genetic information for the production of precision medicine. The company sequences the genetic makeup of a patient to develop a personalized treatment. The company has different sets of gene profiles for detecting the mutation in genes that can lead to solid tumors or malignancy. The company has developed products for cancer detection, including histology genomic tests, ctDNA liquid biopsies, and exosome liquid biopsies.
- Oct 2020Series D$223.6M
- Oct 2020Series C—
- Jan 2020Series C$40.2M
- Nov 2017Series C$101.2M
#9
Deadpooled · Pudong, Shanghai · founded 2016$206.4Mraised▾
Developer of nanocarrier delivery platform for mRNA vaccines. The LPP/mRNA is a patented nano model for delivering mRNA drugs through two-layer structure technology. The company has developed mRNA-based personalized therapeutics which are delivered through the delivery platform for treating cancer, infectious disease, protein defects diseases, and genetic diseases.
- Jun 2021Series C$188M
- Feb 2020Series A$4.3M
- Aug 2019Series A$14.2M
- Seed—
#10
Series C · Shanghai, Shanghai · founded 2009 · 14 employees$97.1Mraised▾
Developer of CAR-T cell therapies for blood cancers and solid tumors. The company has a CoupledCAR technology platform to develop a pipeline of drugs for colorectal, thyroid, pancreatic, and lung cancer.
- Sep 2021Series C$40M
- Dec 2019Series B$28.6M
- Apr 2018Series B$28.5M
#11
Series C · Pudong, Shanghai · founded 2020$46.9Mraised▾
Developer of gene-editing technology to treat genetic diseases. The company develops CRISPR-mediated gene editing and base editing technology to improve gene therapies for the cure of genetic diseases caused by point mutations and cancer.
- Nov 2021Series C$46.9M
#12
Series C · Pudong, Shanghai · founded 2018 · 150 employees$18.5Mraised▾
Developer of gene therapies for the treatment of multiple disease conditions. The company is focusing on gene therapy drugs such as gene replacement and gene editing for rare single-gene genetic diseases. The company's pipeline includes HG-001, HG-202, HG-004, HG-203 for neurodegenerative diseases, visual impairment, and hearing impairment.
- May 2022Series C—
- Dec 2019Series A$14.2M
- Nov 2018Seed$4.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Shanghai is moving
A read on the academic research around Bioinformatics in Shanghai — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 959 papers.
Shanghai's institutions—led by Jiao Tong, Fudan, and SHUTCM—optimistically research single-cell transcriptomics, ferroptosis, and cancer immunotherapy biomarkers, with breakthroughs dominating and concerns minimal.
- Shanghai Jiao Tong University287
- Shanghai University of Traditional Chinese Medicine98
- Fudan University Shanghai Cancer Center61
- Shanghai Ninth People\'s Hospital51
- Shanghai Institute of Materia Medica44
- Transcriptome1→49
- Gene1→43
- CRISPR1→10
- Genome editing1→6
- Virtual screening1→5
- Drug1→8
- Drug discovery1→4
- Genomics1→3
- RNA splicing1→3
- Alternative splicing1→3
- Mechanism (biology)1→15
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.